These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15305425)

  • 1. Safer alternatives to Zelnorm.
    Consum Rep; 2004 Sep; 69(9):47. PubMed ID: 15305425
    [No Abstract]   [Full Text] [Related]  

  • 2. By the way, doctor. I have irritable bowel syndrome, with frequent bloating and constipation. My doctor prescribed a six-week course of Zelnorm, which really helped. Is it safe to take long-term?
    Robb-Nicholson C
    Harv Womens Health Watch; 2005 May; 12(9):8. PubMed ID: 16047399
    [No Abstract]   [Full Text] [Related]  

  • 3. Tegaserod (Zelnorm) for irritable bowel syndrome.
    DeYoung GR
    Am Fam Physician; 2004 Jan; 69(2):363-4. PubMed ID: 14765778
    [No Abstract]   [Full Text] [Related]  

  • 4. Review article: tegaserod -- the global experience.
    Chey WD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischemic colitis, irritable bowel syndrome, and tegaserod--an alternative viewpoint.
    Shetzline MA; Cohard-Radice M; Joelsson B
    Pharmacotherapy; 2005 Nov; 25(11):1684-5; discussion 1685. PubMed ID: 16232032
    [No Abstract]   [Full Text] [Related]  

  • 6. In brief: Tegaserod (Zelnorm) returns.
    Med Lett Drugs Ther; 2019 May; 61(1571):72. PubMed ID: 31169806
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK; Ainsworth MA
    Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC; Barghout V; McBurney CR; Niecko TE
    Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New risk information on IBS drug Zelnorm.
    FDA Consum; 2004; 38(4):6. PubMed ID: 15346569
    [No Abstract]   [Full Text] [Related]  

  • 11. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
    Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
    Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
    Khoshoo V; Armstead C; Landry L
    Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drug approved for irritable bowel syndrome in women.
    Mayo Clin Womens Healthsource; 2004 Feb; 8(2):3. PubMed ID: 14722489
    [No Abstract]   [Full Text] [Related]  

  • 14. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the constipated Asian male more common than we think?
    Gwee KA; Wong RK
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1168-9. PubMed ID: 17688656
    [No Abstract]   [Full Text] [Related]  

  • 17. Review article: the safety profile of tegaserod.
    Schoenfeld P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating functional constipation from constipation-predominant irritable bowel syndrome: management implications.
    Talley NJ
    Rev Gastroenterol Disord; 2005; 5(1):1-9. PubMed ID: 15741927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FDA's decision-making process: isn't it time to temper the principle of protective paternalism?
    Brandt LJ
    Am J Gastroenterol; 2008 May; 103(5):1226-7. PubMed ID: 18477347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegaserod maleate (Zelnorm) for IBS with constipation.
    Med Lett Drugs Ther; 2002 Sep; 44(1139):79-80. PubMed ID: 12237618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.